Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection
Recruiting now · Phase 2 · Has a placebo group
Conditions studied: Viral Pneumonia
In brief
The goal of this Phase 2 study is to assess about the safety, antiviral biomarker responses and efficacy of SNG001 when given to patients requiring invasive mechanical ventilation due to a respiratory virus infection. Its ability to speed up virus clearance and reduce mortality, compared with standard of care, will be studied. The study is split into two parts. All participants will receive standard of care in addition to SNG001 or placebo. In Part 1, the safety of SNG001 will be assessed. Participants of 50 years and older will receive study drug or placebo once a day for up to 14 days, whilst in hospital. In Part 2, the primary objective will be the efficacy of SNG001. Participants between 18 and 50 years with an immunocompromising condition and patients over 50 years (with or without an immunocompromising condition) will receive study drug once a day for up to 14 days, whilst in hospital.
Key facts
- Study ID
- NCT06999603
- Run by
- Synairgen Research Ltd.
- People needed
- 550
- Starts
- 2025-09-02
- Expected to finish
- 2027-05-01
- Last updated by the study team
- 2025-12-31
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Bradford Royal Infirmary — Bradford, United Kingdom (enrolling)
- Leicester Royal Infirmary — Leicester, United Kingdom (enrolling)
- Emory University — Atlanta, Georgia, United States (enrolling)
- Queen Elizabeth Hospital Birmingham — Birmingham, United Kingdom (enrolling)
- Glasgow Royal Infirmary — Glasgow, United Kingdom (enrolling)
- Hull Royal Infirmary — Hull, United Kingdom (enrolling)
- William Beaumont Hospital — Royal Oak, Michigan, United States (enrolling)
- Mayo Clinic - Rochester — Rochester, Minnesota, United States (enrolling)
- Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center — Torrance, California, United States (enrolling)
- Aberdeen Royal Infirmary — Aberdeen, United Kingdom (enrolling)
- Cardiff and Vale Hospital — Cardiff, United Kingdom (enrolling)
- University of North Carolina (UNC) — Chapel Hill, North Carolina, United States (enrolling)
- University of Cincinnati Medical Center (UCMC) — Cincinnati, Ohio, United States (enrolling)
- Sinai-Grace Hospital — Detroit, Michigan, United States (enrolling)
- The Ohio State University (OSU) — Columbus, Ohio, United States (enrolling)
- Mercy St. Vincent Medical Center — Toledo, Ohio, United States (enrolling)
- Oregon Health & Science University (OHSU) — Portland, Oregon, United States (enrolling)
- AnMed Health Pulmonary and Sleep Medicine — Anderson, South Carolina, United States (enrolling)
- Baylor University Medical Center — Dallas, Texas, United States (enrolling)
- Washington University in St. Louis — St Louis, Missouri, United States (enrolling)
- Snake River Research, PLLC — Idaho Falls, Idaho, United States (enrolling)
- Torbay Hospital — Paignton, Devon, United Kingdom (enrolling)
- Northwestern University — Chicago, Illinois, United States (enrolling)
- Royal Sussex County Hospital — Brighton, United Kingdom (enrolling)
- University College London Hospital — London, United Kingdom (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.